HRP20100395T1 - Cjepivo protiv tuberkuloze poboljšane učinkovitosti - Google Patents
Cjepivo protiv tuberkuloze poboljšane učinkovitosti Download PDFInfo
- Publication number
- HRP20100395T1 HRP20100395T1 HR20100395T HRP20100395T HRP20100395T1 HR P20100395 T1 HRP20100395 T1 HR P20100395T1 HR 20100395 T HR20100395 T HR 20100395T HR P20100395 T HRP20100395 T HR P20100395T HR P20100395 T1 HRP20100395 T1 HR P20100395T1
- Authority
- HR
- Croatia
- Prior art keywords
- cell
- cell according
- domain
- nucleic acid
- polypeptide
- Prior art date
Links
- 229960002109 tuberculosis vaccine Drugs 0.000 title 1
- 210000004027 cell Anatomy 0.000 claims abstract 38
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract 27
- 229920001184 polypeptide Polymers 0.000 claims abstract 19
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract 19
- 150000007523 nucleic acids Chemical class 0.000 claims abstract 16
- 108020004707 nucleic acids Proteins 0.000 claims abstract 15
- 102000039446 nucleic acids Human genes 0.000 claims abstract 15
- 230000028993 immune response Effects 0.000 claims abstract 12
- 241000186359 Mycobacterium Species 0.000 claims abstract 7
- 108010046334 Urease Proteins 0.000 claims abstract 7
- 241000124008 Mammalia Species 0.000 claims abstract 5
- 230000002950 deficient Effects 0.000 claims abstract 5
- 210000000680 phagosome Anatomy 0.000 claims abstract 5
- 230000004927 fusion Effects 0.000 claims abstract 4
- 239000000427 antigen Substances 0.000 claims 10
- 102000036639 antigens Human genes 0.000 claims 10
- 108091007433 antigens Proteins 0.000 claims 10
- 230000001580 bacterial effect Effects 0.000 claims 8
- 229960005486 vaccine Drugs 0.000 claims 8
- 230000001939 inductive effect Effects 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 241000186366 Mycobacterium bovis Species 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 4
- 230000002163 immunogen Effects 0.000 claims 4
- 239000002773 nucleotide Substances 0.000 claims 4
- 125000003729 nucleotide group Chemical group 0.000 claims 4
- 101710088334 Diacylglycerol acyltransferase/mycolyltransferase Ag85B Proteins 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000008827 tuberculosis Diseases 0.000 claims 3
- 241000186781 Listeria Species 0.000 claims 2
- 239000000969 carrier Substances 0.000 claims 2
- 238000004113 cell culture Methods 0.000 claims 2
- 230000001413 cellular effect Effects 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 2
- 239000000945 filler Substances 0.000 claims 2
- 238000003780 insertion Methods 0.000 claims 2
- 230000037431 insertion Effects 0.000 claims 2
- 230000003834 intracellular effect Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 244000045947 parasite Species 0.000 claims 2
- 230000002688 persistence Effects 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- 101710166488 6 kDa early secretory antigenic target Proteins 0.000 claims 1
- 101710088335 Diacylglycerol acyltransferase/mycolyltransferase Ag85A Proteins 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 210000002540 macrophage Anatomy 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 238000007493 shaping process Methods 0.000 claims 1
- 208000014794 superficial urinary bladder carcinoma Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US46464403P | 2003-04-23 | 2003-04-23 | |
PCT/EP2004/004345 WO2004094469A1 (en) | 2003-04-23 | 2004-04-23 | Tuberculosis vaccine with improved efficacy |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20100395T1 true HRP20100395T1 (hr) | 2010-09-30 |
Family
ID=33310924
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20100395T HRP20100395T1 (hr) | 2003-04-23 | 2010-07-19 | Cjepivo protiv tuberkuloze poboljšane učinkovitosti |
Country Status (24)
Country | Link |
---|---|
US (2) | US7988980B2 (pt) |
EP (1) | EP1618128B1 (pt) |
JP (1) | JP4662925B2 (pt) |
KR (1) | KR101101263B1 (pt) |
CN (1) | CN1798762B (pt) |
AT (1) | ATE473238T1 (pt) |
AU (1) | AU2004232485B2 (pt) |
BR (1) | BRPI0409789B8 (pt) |
CA (1) | CA2523084C (pt) |
CU (1) | CU23608A3 (pt) |
CY (1) | CY1110793T1 (pt) |
DE (1) | DE602004028000D1 (pt) |
DK (1) | DK1618128T3 (pt) |
ES (1) | ES2344698T3 (pt) |
HK (1) | HK1091217A1 (pt) |
HR (1) | HRP20100395T1 (pt) |
MX (1) | MXPA05011360A (pt) |
PL (1) | PL1618128T3 (pt) |
PT (1) | PT1618128E (pt) |
RU (1) | RU2342400C2 (pt) |
SI (1) | SI1618128T1 (pt) |
UA (1) | UA91180C2 (pt) |
WO (1) | WO2004094469A1 (pt) |
ZA (1) | ZA200508276B (pt) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL1618128T3 (pl) * | 2003-04-23 | 2010-12-31 | Max Planck Gesellschaft | Szczepionka przeciwko gruźlicy o ulepszonej skuteczności |
EP1649869A1 (en) * | 2004-10-21 | 2006-04-26 | Vakzine Projekt Management GmbH | Combination of a recombinant mycobacterium and a biologically active agent as a vaccine |
ZA200704765B (en) | 2004-12-01 | 2008-09-25 | Aeras Global Tb Vaccine Found | Recombinant BCG strains with enhanced ability to escape the endosome |
EP2244720A4 (en) * | 2008-01-11 | 2013-01-16 | Us Gov Health & Human Serv | POLYPEPTIDE VACCINE AND VACCINE STRATEGY AGAINST MYCOBACTERIUM |
WO2011031139A1 (en) | 2009-09-09 | 2011-03-17 | Universiteit Utrecht Holding B.V. | An ataq protein or a part thereof as a vaccine |
SA110310855B1 (ar) | 2009-11-13 | 2014-09-16 | Laboratories Leti S L Unipersonal | استخدام مصدر l3 و/ أو l5 كلقاح أو كوسيلة تشخيصية لمرض طفيلي |
BR112013004389A2 (pt) | 2010-08-27 | 2016-05-17 | Pantarhei Bioscience Bv | método imunoterapêutico para tratamento do câncer de próstata |
SG188595A1 (en) * | 2010-09-20 | 2013-04-30 | Vakzine Projekt Man Gmbh | Recombinant mycobacterium as vaccine for use in humans |
US9187751B2 (en) | 2010-11-10 | 2015-11-17 | Laboratorios Leti, S.L. | Adjuvant |
MX345575B (es) * | 2010-12-21 | 2017-02-03 | Max-Planck-Gesellschaft Zur Förderung Der Wss E V | Micobacteria recombinante como vacuna. |
PL2656070T3 (pl) | 2010-12-21 | 2017-01-31 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Oznaczanie skuteczności żywej rekombinowanej szczepionki anty-mykobakteryjnej |
RU2520078C1 (ru) * | 2013-04-25 | 2014-06-20 | Федеральное государственное бюджетное учреждение "Научно-исследовательский институт эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации (ФГБУ "НИИЭМ им. Н.Ф. Гамалеи" Минздрава России) | СПОСОБ ПОЛУЧЕНИЯ ИММУНОГЕННОЙ КОМПОЗИЦИИ НА ОСНОВЕ ГИБРИДНОГО БЕЛКА Ag85A-DBD И ДЕКСТРАНА, РЕКОМБИНАНТНАЯ ПЛАЗМИДА pAg85A-DBD, ШТАММ Escherichia coli [pREP4, pAg85A-DBD], ХИМЕРНЫЙ БЕЛОК Ag85A-DBD |
WO2016080830A2 (en) | 2014-11-18 | 2016-05-26 | Pantarhei Bioscience B.V. | Immunotherapeutic method for treating pancreatic cancer |
EP3090757A1 (en) * | 2015-05-04 | 2016-11-09 | Vakzine Projekt Management GmbH | Recombinant mycobacterium as an immunotherapeutic agent for the treatment of cancer |
EP3349790A1 (en) | 2015-09-18 | 2018-07-25 | Rijksuniversiteit Groningen | Long chain inulin for stimulating an immune response |
KR101825439B1 (ko) * | 2016-04-15 | 2018-02-05 | 배재대학교 산학협력단 | 염산 처리에 의한 그람양성 박테리아 고스트의 제조 방법 |
CN110506108B (zh) * | 2017-04-07 | 2023-10-24 | 成都安永鼎业生物技术有限公司 | 过表达phoP-phoR的重组BCG |
WO2019021064A1 (en) * | 2017-07-25 | 2019-01-31 | Aurora Labs Ltd | CONSTRUCTION OF SOFTWARE DELTA UPDATES FOR VEHICLE ECU SOFTWARE AND TOOL-BASED ANOMALY DETECTION |
RU2678175C1 (ru) * | 2018-03-16 | 2019-01-23 | федеральное государственное бюджетное учреждение "Научно-исследовательский институт гриппа имени А.А. Смородинцева" Министерства здравоохранения Российской Федерации (ФГБУ "НИИ гриппа им. А.А. Смородинцева" Минздрава России) | Рекомбинантный штамм вируса гриппа A/PR8/HK-NS80E85A, экспрессирующий фрагменты антигенов ESAT-6 и Ag85A M.tuberculosis, для получения векторной вакцины против туберкулеза |
CN111979162B (zh) * | 2019-05-22 | 2024-02-13 | 上海市公共卫生临床中心 | 重组卡介苗菌株、其制备方法和用途 |
WO2021228363A1 (en) | 2020-05-11 | 2021-11-18 | Vakzine Projekt Management Gmbh | Prevention of infectious diseases by modulating the immune system |
EP4149529A1 (en) | 2020-05-11 | 2023-03-22 | Vakzine Projekt Management GmbH | Prevention of infectious diseases by modulating the immune system |
EP4373519A1 (en) | 2021-07-22 | 2024-05-29 | Serum Life Science Europe GmbH | Recombinant mycobacterium as an immunotherapeutic agent for the second-line therapy of bladder carcinoma |
EP4122491A1 (en) | 2021-07-22 | 2023-01-25 | Vakzine Projekt Management GmbH | Recombinant microbacterium as an immunotherapeutic agent for the second-line therapy of bladder carcinoma |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0902086A1 (en) | 1997-08-22 | 1999-03-17 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Tuberculosis vaccine |
PL1618128T3 (pl) * | 2003-04-23 | 2010-12-31 | Max Planck Gesellschaft | Szczepionka przeciwko gruźlicy o ulepszonej skuteczności |
-
2004
- 2004-04-23 PL PL04729090T patent/PL1618128T3/pl unknown
- 2004-04-23 US US10/554,408 patent/US7988980B2/en active Active
- 2004-04-23 DE DE602004028000T patent/DE602004028000D1/de not_active Expired - Lifetime
- 2004-04-23 RU RU2005136354/13A patent/RU2342400C2/ru active
- 2004-04-23 AU AU2004232485A patent/AU2004232485B2/en not_active Expired
- 2004-04-23 WO PCT/EP2004/004345 patent/WO2004094469A1/en active Application Filing
- 2004-04-23 DK DK04729090.3T patent/DK1618128T3/da active
- 2004-04-23 AT AT04729090T patent/ATE473238T1/de active
- 2004-04-23 CN CN2004800106640A patent/CN1798762B/zh not_active Expired - Lifetime
- 2004-04-23 ES ES04729090T patent/ES2344698T3/es not_active Expired - Lifetime
- 2004-04-23 MX MXPA05011360A patent/MXPA05011360A/es active IP Right Grant
- 2004-04-23 UA UAA200510351A patent/UA91180C2/ru unknown
- 2004-04-23 CA CA2523084A patent/CA2523084C/en not_active Expired - Lifetime
- 2004-04-23 JP JP2006505250A patent/JP4662925B2/ja not_active Expired - Lifetime
- 2004-04-23 SI SI200431506T patent/SI1618128T1/sl unknown
- 2004-04-23 KR KR1020057020036A patent/KR101101263B1/ko active IP Right Grant
- 2004-04-23 BR BRPI0409789A patent/BRPI0409789B8/pt active IP Right Grant
- 2004-04-23 PT PT04729090T patent/PT1618128E/pt unknown
- 2004-04-23 EP EP04729090A patent/EP1618128B1/en not_active Expired - Lifetime
-
2005
- 2005-10-13 ZA ZA200508276A patent/ZA200508276B/en unknown
- 2005-10-26 CU CU20050206A patent/CU23608A3/es active IP Right Grant
-
2006
- 2006-10-27 HK HK06111864.4A patent/HK1091217A1/xx not_active IP Right Cessation
-
2010
- 2010-07-19 HR HR20100395T patent/HRP20100395T1/hr unknown
- 2010-09-16 CY CY20101100846T patent/CY1110793T1/el unknown
-
2011
- 2011-06-22 US US13/165,904 patent/US8545854B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20100395T1 (hr) | Cjepivo protiv tuberkuloze poboljšane učinkovitosti | |
Dhama et al. | DNA vaccines and their applications in veterinary practice: current perspectives | |
US6855320B2 (en) | Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity | |
Muhammad et al. | Bacterial ghosts as carriers of protein subunit and DNA-encoded antigens for vaccine applications | |
Sáez et al. | Oral immunization of mice with recombinant Lactococcus lactis expressing Cu, Zn superoxide dismutase of Brucella abortus triggers protective immunity | |
Al-Mariri et al. | Yersinia enterocolitica as a vehicle for a naked DNA vaccine encoding Brucella abortus bacterioferritin or P39 antigen | |
US20070003567A1 (en) | Composition and methods for enhancing immunogenecity of antigens | |
EP1537214B1 (en) | Regulated bacterial lysis for gene vaccine vector delivery and antigen release | |
JP2001514000A5 (pt) | ||
Cassataro et al. | Improved immunogenicity of a vaccination regimen combining a DNA vaccine encoding Brucella melitensis outer membrane protein 31 (Omp31) and recombinant Omp31 boosting | |
Brockstedt et al. | Promises and challenges for the development of Listeria monocytogenes-based immunotherapies | |
US9078844B2 (en) | Combination of a bacterial cell and a biologically active agent | |
Rashid et al. | Enhancement of the protective efficacy of a ROP18 vaccine against chronic toxoplasmosis by nasal route | |
Hajam et al. | Incorporation of membrane-anchored flagellin into Salmonella Gallinarum bacterial ghosts induces early immune responses and protection against fowl typhoid in young layer chickens | |
Pollak et al. | Immunization with Brucella VirB proteins reduces organ colonization in mice through a Th1-type immune response and elicits a similar immune response in dogs | |
Al-Mariri et al. | Efficacy evaluation of live Escherichia coli expression Brucella P39 protein combined with CpG oligodeoxynucleotides vaccine against Brucella melitensis 16M, in BALB/c mice | |
CA3202257A1 (en) | Compositions and methods | |
ES2315281T3 (es) | Vacunas de bcg recombinante contra agentes patogenos intracelulares y metodos de uso de las mismas. | |
Golshani et al. | Comparison of the protective immunity elicited by a Brucella cocktail protein vaccine (rL7/L12+ rTOmp31+ rSOmp2b) in two different adjuvant formulations in BALB/c mice | |
Kim et al. | Construction of an inactivated typhoid vaccine candidate expressing Escherichia coli heat-labile enterotoxin B subunit and evaluation of its immunogenicity in a murine model | |
Ali et al. | CTL responses to Leishmania mexicana gp63‐cDNA vaccine in a murine model | |
Chaudhuri et al. | Cloning of 87 k D a outer membrane protein gene of Pasteurella multocidaP 52 | |
US7569552B2 (en) | DNA vaccines against tumor growth and methods of use therof | |
Shahzad et al. | Evaluation of DNA vaccines encoding M. Tb gene Bfrb and Mpt32 in mice model | |
Wengui et al. | Construction, Identification, and Expression of Lactococcus lactis-Based Recombinant Vaccine for Echinococcus granulosus |